Fresenius Kabi, a global healthcare company specializing in medicines and technologies, has announced the availability of its first immunology biosimilar, IDACIO® (adalimumab-aacf), in the United States. IDACIO® is indicated for use in the treatment of chronic autoimmune diseases and is a biosimilar to Humira® (adalimumab). It is available in a self-administered prefilled syringe and pre-filled ..
Jubilant Therapeutics is preparing to begin Phase II and first-in-human trials later in 2023 with two Orphan Drug Designations, an advantageous safety profile, and enhanced therapeutic indices. The company's pipeline uses their Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine to identify candidate molecules with improved therapeutic indices and the ability to penetrate ..
Jubilant Therapeutics, a precision oncology and immunology-focused biotech, is set to begin Phase II and first-in-human trials in 2023 with two Orphan Drug Designations. Their pipeline is generated entirely in-house using their unique discovery engine called the Therapeutic Index and Brain Exposure Optimization (TIBEO) which identifies candidate molecules with enhanced therapeutic indices that c..
Jubilant Therapeutics is gearing up for Phase II and first-in-human trials in 2023 with its pipeline of precision medicines that offer safety and therapeutic advantages in cancer and immunology. The company's drug discovery approach focuses on developing candidates through clinical proof of concept, partnering those assets with companies to advance them through late-stage clinical development an..
Jubilant Therapeutics is preparing for Phase II and first-in-human trials later in 2023, with two Orphan Drug Designations, an advantageous safety profile and enhanced therapeutic indices. The company's pipeline is generated 100% in-house using its Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine, which permits the identification of candidate molecules with enhanced the..
Merck & Co has acquired Prometheus Biosciences, Inc. for $10.8 billion, making it a wholly-owned subsidiary and helping Merck expand its presence in immunology while strengthening its pipeline with a potential best-in-class candidate for immune-mediated diseases such as ulcerative colitis and Crohn’s disease. The leading clinical candidate, PRA-023, is now known as MK-7240 and is a humanized mon..
